{
  "docId": "019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "docSlug": "58255c61d2bdadc3239a5fe01efc41e1",
  "documentTitle": "BioNTech | Results Presentation Deck | 43 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 43,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "other",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de071-5aa5-74ef-a452-60fcbf49cdc6/40",
  "deckHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "deckJsonHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6.json",
  "deckAnchorHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.04,
        "y": 0.68
      },
      "kind": "list",
      "text": "Strategic rationale: Add turn-key U.S. cell therapy facility to complement existing facility in Idar-Oberstein, Germany; Enable expansion of U.S. clinical supply of CARVac and other BioNTech cell therapies; Strengthen U.S. team with highly skilled TCR scientists and manufacturing workforce; Expand BioNTech's proprietary cell therapy pipeline and capabilities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "602adc02-83ec-4a03-9b4d-a05c2b46c4ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.04,
        "y": 0.4
      },
      "kind": "list",
      "text": "What we gain: Leased U.S. clinical-stage cell therapy manufacturing facility in Gaithersburg, Maryland; Brings more than 50 highly trained cell & gene therapy scientists and production experts; Personalized Neo-antigen TCR program; Library of other preclinical TCR assets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66f9a12a-a800-4911-8d8b-acfd1f36fbd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "Transaction overview: On July 19, BioNTech announced an asset purchase agreement with Kite to acquire its Neoantigen TCR Cell Therapy R&D Platform and cGMP manufacturing facility in the U.S. Transaction closed on August 4, 2021",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7ffcbed-34f2-491c-a2a8-252ce88bd423",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "Acquisition of Kite's Solid Tumor TCR-T cell platform and related assets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f350a3d2-21ef-4b93-8181-135d138c6da2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "14c5b1a3-6dea-44a6-b94a-2b16899a509b",
      "evidence": "list/bullet: Strategic rationale: Add turn-key U.S. cell therapy facility to complement existing facility in Idar-Oberstein, Germany; Enable expansion of U.S. clinical supply of CARVac and other BioNTech cell therapies;",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 42,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6afc8369-9bbf-45e1-a77c-ba4d4e30b836",
      "evidence": "The document uses the Golden Circle framework to explain its vision, strategy, and achievements",
      "position": 0,
      "objective": "To explain why BioNTech's vision and strategy are important for the future of immunotherapy",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}